drugset
drugset / Trial / NCT06309277

A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDD

NCT06309277 ↗

Phase 2 Completed 46 enrolled Gilgamesh Pharmaceuticals
RandomizedCrossoverQuadruple-blindTreatment

Summary

The aim of this Phase 2a study in patients with MDD is to assess safety and tolerability and preliminary antidepressant efficacy.

Timeline

Start
2024-02-01
Primary completion
2025-03-04
Completion
2025-03-27

Drugs

EvaluationDrugModalityDoseRoute
Subject GM-1020 Unknown — Oral

Indications

major depressive disorder